PolyActiva has showcased their Phase 2 clinical data for their lead candidate PA5108 Ocular Implant in glaucoma patients.

Patients received continuous therapy for intraocular pressure (IOP) for over 48 weeks, receiving their first and second implants at week 0 and 21 respectively. Clinically meaningful IOP reductions of 26-35% were observed  over the 48-week treatment period, and 94% of patients did not require additional drop therapy.

PolyActiva has recently been awarded a $1.5m CUREator Grant, which will be used to progress its second generation ocular implant as a treatment for patients with glaucoma, targeting sustained daily dosing for 12 months.

PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.

The interim Phase 2a results demonstrate a sustained >20% reduction of IOP after 6 months with a favorable safety profile.

PolyActiva presents positive clinical trial results at the 2022 American Glaucoma Society Annual Meeting – March 2022

PolyActiva announces positive Phase IIa results in glaucoma trial with low dose cohort.

PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.

PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors.

PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.

PolyActiva commences its first Phase I clinical trial.

PolyActiva raises AUD$9.2M in Series B venture funding.